Takeda and Lundbeck lay out Phase III plans under depression alliance
This article was originally published in Scrip
Takeda and Lundbeck have unveiled details of new pivotal Phase III programmes for two novel molecules for major depressive disorder (MDD) being co-developed under their 2007 alliance for mood and anxiety disorder drugs.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.